Table 1.
Reports of refractive error after the use of anti-vascular endothelial growth factor agents for the treatment of retinopathy of prematurity
| Study | Location | Mean GA (weeks) | Mean BW (g) | Mean AA at Tx (weeks) | Refracted eyes, n | Refraction age (months) | Anti-VEGF, dose (mg) | Mean SE ± SD (D), anti-VEGF Tx | Mean SE ± SD (D), laser Tx |
|---|---|---|---|---|---|---|---|---|---|
| Wu et al20 | Taiwan | 26.3 IVB | 930.1 IVB | 36.6 IVB | 53 IVB 14 IVB + CLT |
17.8 | IVB, 0.625 | −0.1±1.8 | NA |
| Martínez-Castellanos et al21 | Mexico | 29.3 IVB | 1,233.3 IVB | 25.2 IVB | 9 IVB | 60 | IVB, 1.25 | −1.75 | NA |
| Harder et al22 | Germany | 25.2 IVB 25.3 CLT |
622 IVB 717 CLT |
25.2 IVB 25.3 CLT |
23 IVB 26 CLT |
11.4 | IVB, 0.375 or 0.625 |
−1.04±4.24 | −4.41±5.5 |
| Chen et al23 | Taiwan | 26.4 IVB | 882.2 IVB | 35 | 40 IVB 17 IVB + CLT |
24 | IVB, 0.625 | −0.98±4.05 | IVB + CLT: −2.4 |
| Geloneck et al1 | USA | 24.4 IVB 24.2 CLT |
652.1 IVB 669.3 CLT |
35.1 IVB 34.8 CLT |
110 IVB 101 CLT |
30 IVB 30 CLT |
IVB, 0.625 | Zone I: −1.51±3.42 Zone II: −0.58±2.53 |
Zone I: −8.44±7.57 Zone II: −5.83±5.87 |
| Salman and Said24 | Egypt | 26.3 IVA | 991 IVA | NA | 26 IVA | 12 | IVA, 1 | 0.75 | NA |
| Isaac et al25 | Canada | 25.2 IVB 25 CLT |
722 IVB 674 CLT |
37.6 IVB 36.7 CLT |
23 IVB 22 CLT |
12 | IVB, 0.625 | −3.57±6.19 | −6.39±4.41 |
| Kuo et al26 | Taiwan | NA | NA | NA | 14 IVB 15 CLT |
36 | NA | −1.53±2.2 | −1.71±1.27 |
| Chen et al27 | Taiwan | 26.5 IVB 26.2 IVR |
869.1 IVB 848.8 IVR |
36.8 IVB 36.4 IVR |
41 IVB 31 IVR |
12 | IVB, 0.625 IVR, 0.25 |
−0.3 IVB +0.1 IVR |
iVB + CLT: −2.4 |
| Hwang et al28 |
USA | 24.2 IVB 24.8 CLT |
668.1 IVB 701.4 CLT |
35.1 IVB 36.1 CLT |
22 IVB 32 CLT |
22.4 IVB 37.1 CLT |
IVB, 0.625 | −2.4 (zone I, −3.7; zone II, 0.6) |
−5.3 (zone I, −10.1; zone II, −4.7) |
| Gunay et al29 | Brazil | 26.4 IVB 27.3 CLT |
901.4 IVB 941 CLT |
34.0 IVB 33.9 CLT |
43 IVB 35 CLT |
24 | IVB, 0.625 | 0.42±3.42 | −6.66±4.96 |
Abbreviations: CLT, conventional laser therapy; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVA, intravitreal aflibercept; GA, gestational age; BW, birth weight; AA, adjusted age; Tx, treatment; SD, standard deviation; SE, spherical equivalent refractive error; NA, not available.